Who we are

  • Inbiose is a leading B2B Biotech Company with focus on the development of specialty glycans, in particular Human Milk Oligosaccharides (HMOs)

  • We have a proven track record in developing cost-effective processes for large scale HMO production, based on our proprietary GlycoActives® technology

  • What was started in 2013 as a spinoff from the University of Ghent, we are now the biggest private research group in the world of specialty glycans. 

2017-11-09-CVE-Inbiose-784

Our focus

  • Inbiose is dedicated to developing specialty glycans that are known to influence health, either directly or indirectly through modulation of the microbiome.

  • We continuously improve our technology platform based on latest advancements into biotech, bio-informatics and health sciences.

  • We strive to make these specialty glycans  available for

    mainstream uses, minimizing time to market, to the benefit of all.

2017-11-09-CVE-Inbiose-561-2

Our story

Following some scientific breakthroughs demonstrating the potential to efficiently manufacture specialty glycans using white biotechnology, Inbiose origin is at the University of Ghent-Belgium, where it was founded in 2013.

Since then, the company has grown consistently and we’re proud to have build a team of 50 highly skilled and committed, mainly bio-engineers and bio-informatics.

Inbiose has its offices and lab in the Technology Park in Ghent-Belgium, which is second largest Biotech hub in the world.

Our story

Leading the way in specialty carbohydrates